Potential interaction between ritonavir and carbamazepine

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 851-854

  Kato, Yasuhiro ^a,d   Fujii, Teruhisa ^a   Mizoguchi, Nobuyuki ^a   Takata, Noboru ^a   Ueda, Kazuhiro ^a   Feldman, Mitchell D ^b   Kayser, Steven R ^c  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d National Hiroshima Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; RITONAVIR;

ANTICONVULSANT THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIVER DYSFUNCTION; LIVER FUNCTION; PATIENT MONITORING; VERTIGO; VOMITING;

EID: 0033917785     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.851.35206     Document Type: Article

References (15)

1. Barry M, Gibbons S, Back D. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
2. Sahai J. Risks and synergies from drug interactions. AIDS 1996;10(suppl 1):S21-5.
3. BHIVA Guidelines Co-ordinating Committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
4. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-9.
5. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:2000-2.
6. Steven GD. Antiretroviral agents: the next generation. AIDS Clin Care 1998;10:33-6, 39-40.
7. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
8. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome p450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
9. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. Clin Pharmacokinet 1996;31:198-214.
10. Flexner C. Drug therapy: HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
11. Elwes RD, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigapentin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996;30:403-15.
12. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996;31:470-93.
13. Shorvon S, Stefan H. Overview of the safety of the newer antiepileptic drugs. Epilepsia 1997;38(suppl 1):S45-51.
14. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38(suppl 1):S18-23.
15. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.